Clinical significance of HIV-1 coreceptor usage

Hanneke Schuitemaker1,3†, Angélique B van ‘t Wout1,3†, Paolo Lusso2†

Abstract

The identification of phenotypically distinct HIV-1 variants with different prevalence during the progression of the disease has been one of the earliest discoveries in HIV-1 biology, but its relevance to AIDS pathogenesis remains only partially understood. The physiological basis for the phenotypic variability of HIV-1 was elucidated with the discovery of distinct coreceptors employed by the virus to infect susceptible cells. The role of the viral phenotype in the variable clinical course and treatment outcome of HIV-1 infection has been extensively investigated over the past two decades. In this review, we summarize the major findings on the clinical significance of the HIV-1 coreceptor usage.

Introduction

The entry of human immunodeficiency virus (HIV) into cells is critically dependent on the sequential interaction of the viral envelope with two cell-surface receptors, the CD4 glycoprotein and a 7-transmembrane-domain chemokine receptor such as CCR5 or CXCR4. The evolutionary choice of HIV of exploiting chemokine receptors as entry gateways has established a tight biological bond between HIV and the chemokine system, turning the natural ligands of these receptors into specific viral inhibitors. The first encounter between the fields of HIV and chemokines occurred unexpectedly at the end of 1995 with the discovery that three chemokines of the CC family, RANTES (CC-chemokine ligand 5 or CCL5), MIP-1α (CCL3) and MIP-1β (CCL4), act as potent and specific natural inhibitors of HIV-1 infection [1]. A few months later, in the spring of 1996, a totally independent experimental approach led to the identification of a chemokine receptor, CXCR4, as a critical cell-surface coreceptor for HIV-1 entry [2]. These two complementary findings triggered an authentic chain reaction of further breakthroughs, most notably the discovery of the second major HIV-1 coreceptor (i.e., CCR5), the identification of a specific chemokine ligand for CXCR4 (i.e., SDF-1/CXCL12), and the first definitive association of a genetic determinant (i.e., CCR5-Δ32) with HIV-1 resistance (reviewed in [3]). Looking backward, the exploration of this uncharted area of investigation has greatly advanced our understanding of the biology and pathogenesis of HIV infection, opening new perspectives for the development of effective measures for the therapy and prevention of AIDS.

CCR5 and CXCR4: the two clinically relevant HIV-1 coreceptors

Although several chemokine receptors may function as HIV-1 coreceptors in vitro, multiple lines of clinical and experimental evidence indicate that only two of them, CCR5 and CXCR4, have bona fide clinical relevance (reviewed in [3]). Both CCR5 and CXCR4 are expressed, in combination with CD4, on all the relevant target cells for HIV-1, including primary CD4⁺ T cells, macrophages and dendritic cells. Individual viral isolates are presently classified based on their ability to use CCR5 (R5 variants), CXCR4 (X4 variants) or both coreceptors (R5X4 variants) [4]). The dual-tropic R5X4 viruses are further classified as Dual-R (R5X4 variants with more efficient use of CCR5 than of CXCR4) or Dual-X (R5X4 with more efficient use of CXCR4 than of CCR5) [5-7]. In the absence of a more accurate characterization, bulk viral isolates capable of using both coreceptors are designated dual/mixed (D/M) as their quasispecies may contain any mixture of the various phenotypic variants (Figure 1).

Ex vivo determination of HIV-1 coreceptor usage

Before the identification of the coreceptors, HIV-1 isolates were characterized based on their ability to infect
and induce syncytia ( multinucleated giant cells ) in CD4+ T-cell lines that express CXCR4 but not CCR5. Using the MT-2 cell line as a prototype, viruses that did not infect MT-2 cells were designated non-syncytium inducing (NSI), while viruses that did infect MT-2 cells were designated syncytium inducing (SI).

Today, we attribute this differential ability to the viral coreceptor usage, and MT-2-positive variants are defined as either X4 or R5X4 [4]. Of note, the MT-2 assay can only detect CXCR4-using variants, and the absence of viral growth in MT-2 can be due either to the exclusive presence of R5 variants or to the failure to isolate HIV. For a precise determination of the coreceptor use of HIV-1 isolates, cell lines such as U87 and GHOST transfected with CCR5, CXCR4, or other coreceptors, have been used [8,9]. More recently, several recombinant phenotypic assays to determine coreceptor usage have been developed, such as the Trofile assay (Monogram Biosciences) [10]. Patient plasma is used to generate pseudoviruses or infectious recombinant viruses that include full-length or partial viral envelopes derived from the patient's virus population. The recombinants are subsequently tested on indicator cell lines expressing CD4 and either CCR5 or CXCR4. While the sensitivity of the Trofile assay for detecting CXCR4-using HIV-1 is similar to that of the MT-2 test [11], recombinant phenotypic assays are able to distinguish pure R5, D/M and pure X4 populations.

### HIV-1 coreceptor usage and genetic subtypes

The use of different coreceptors by HIV-1 is a general phenomenon that has been observed for viruses from all different genetic subtypes and circulating recombinant forms (CRFs) [12,13]. However, quantitative differences in the prevalence of CXCR4 usage among subtypes exist. Most of the initial studies on HIV-1 coreceptor usage evolution were performed on strains belonging to genetic subtype-B [14,15], which remains the best characterized subtype in terms of coreceptor usage. However, a more complex picture has been delineated with the extension of these studies to non-B HIV-1 subtypes.

One of the major discrepancies was the observation of a low frequency of CXCR4 usage among subtype-C strains [16-21]. Infection with subtype-C HIV-1 accounts for over half of the worldwide HIV-1 epidemics [22], and is as deadly as subtype-B infection. Although it has been suggested that the underrepresentation of CXCR4-using strains in these reports might be due to a sampling bias, later studies in treatment-experienced patients from Zimbabwe [23] and a recent study from South Africa have reported a higher prevalence of CXCR4-using variants than in the past [24].
sugesting an ongoing evolution of the subtype-C HIV-1 epidemic in Africa (see below).

An inverse skewing in coreceptor usage, with an increased presence of CXCR4-using strains, has instead been reported for subtype-D HIV-1 [5,12,25]. This observation is consistent with the faster pace of disease progression reported for subtype-D infection both in Africa [25-27] and outside Africa [28]. An increased rate of CXCR4 usage has also been reported in a study on a limited number of subtype-AE isolates [29,30]. Even more complex is the situation with mixed genotypes with only a few isolates so far characterized [31,32]. In a recent study in Guinea Bissau, an increasing and generally high frequency of CXCR4 tropism (86%) was observed in CRF02_AG [33].

Molecular determinants of HIV-1 coreceptor usage

Studies conducted with subtype-B variants have shown that the HIV-1 coreceptor usage is determined by the viral envelope, primarily the second and third variable loops (V2 and V3) of the external HIV-1 envelope glycoprotein, gp120 [34-37]. Specifically, the presence of a positively-charged amino acid at either one or both of two specific positions in the V3 loop (positions 11 and 25) is strongly associated with a CXCR4-using phenotype in subtype-B primary isolates [38,39], suggesting that these amino acids play a crucial role in the interaction of gp120 with the coreceptors. Indeed, it has been shown that the V1V2 and V3 regions are involved in the interaction with CCR5 and CXCR4 [40-42]. This model is compatible with insights from structural studies in which V3 and a conserved coreceptor-binding site that includes the stem of the V1V2 loop are involved in coreceptor binding. In various trimeric models of the gp41-gp120 envelope glycoprotein complex, V2 directly interacts with V3 and both participate in coreceptor binding [43-46].

As shown for subtype-B HIV-1, the V3 loop also seems to be the principal genetic determinant of the coreceptor choice among subtype-D (10 variants studied) and subtype-A (one variant studied) [12]. In later studies, subtype-C CXCR4-using strains did not show the same dependence as other subtypes on positively-charged residues in the V3 loop [47,48].

Predictive algorithms of HIV-1 coreceptor usage

The identification of viral genotypic changes associated with different coreceptor usage has led to the development of sequence-based algorithms to predict coreceptor usage. Starting with the 11/25 rule derived from subtype-B variants [39], efforts have concentrated mainly on identifying sequence patterns in the V3 loop. Most genotypic predictors of coreceptor usage incorporate information from across the V3 region (Table 1) [49-53], in some cases along with genotypic correlates outside the V3 [54]. Some methods also incorporate clinical data [55]. Progress is also being made on the inclusion of structural information to assist prediction [56], as well as on the ability to discriminate between X4 and R5X4 virus [57]. On cloned viruses belonging to genetic subtype B, the specificity and sensitivity of most predictive methods exceed 90% and 80%, respectively. However, the sensitivity drops below 50% when bulk uncloned sequences and non-subtype B viruses are assayed. Moreover, technical limitations to the generation of unambiguous DNA sequences from the HIV-1 envelope region that has insertions and deletions that prevent the generation of interpretable electropherograms, interfere with a predictive determination of tropism in a significant fraction of patient samples. This in combination with the limited predictive power obviously has implications for a clinical diagnostic application of bulk sequencing technology and current predictive algorithms for HIV-1 coreceptor usage. To date, studies of genotypic predictors have been retrospective with patient samples selected based on availability of phenotypic tropism determinations. Prospective studies will be needed to firmly establish the clinical usefulness of genotypic tropism determination.

As discussed below, the selective pressure that leads to the emergence of CXCR4-using strains is complex and

| Predictor        | URL                                          | Method                       | Ref     |
|------------------|----------------------------------------------|------------------------------|---------|
| R5/X4 and NSISI network | http://cancer.med.unc.edu/swanstromlab/resources.html | Neural network             | Resch et al, 2001 |
| WebPSSM          | http://indra.mullins.microbiol.washington.edu/webpssm/ | PSSM                         | Jensen et al, 2003 |
| WetCat           | http://genomiac2.ucsd.edu:8080/wetcat/v3.html | SVM                          | Pillai et al, 2003 |
| Geno2pheno       | http://coreceptor.bioinf.mpi-inf.mpg.de/      | SVM                          | Sing et al, 2007 |
| V3SD             | The source code for prediction and analysis is available upon request. | SVM                          | Sander et al, 2007 |
| R5/X4-pred       | http://psy.ujs.edu.cn/R5-X4_pred.rar          | Random forests               | Xu et al, 2007   |
| ANN              | Not available                                | Neural network               | Lamers et al, 2008 |
| hiv-dskernel     | http://genome.ulaval.ca/hiv-dskernel         | SVM                          | Boisvert et al, 2008 |
variable, and clinically relevant CXCR4-using minorities may coexist with a predominant R5 virus, even though they remain rare enough to go undetected by sequencing [58]. In addition, not all determinants of coreceptor usage lie within the V3 loop, the region employed by most current predictors [35,59]. Accurate prediction is also complicated by the fact that the V3-C4 region of the envelope gene, which has the greatest influence on tropism, also has a relatively high rate of diversity although the V3 region itself does contain conserved segments [60]. This complicates the interpretation of sequences, especially when so-called bulk sequencing is employed. This method captures only the most prevalent sequence (>25% of the total quasispecies), and the results become difficult to interpret when many genetic variants are present simultaneously. However, continuous progress is being made, especially with the application of next generation sequencing [61].

Clinical trials with CCR5 antagonists have indicated that patients with detectable CXCR4-using virus are unlikely to show a significant decrease in viral load in response to CCR5 antagonists [62,63]. Therefore, prior to initiating treatment with CCR5 inhibitors, patients are now screened to exclude those who harbor CXCR4-using variants. Both phenotypic and genotypic assays have been developed for this screening, but the Monogram Trofile assay is currently the only clinically validated test and has been used to screen the largest number of patients [10,64]. As more combined V3 genotype-phenotype data become available, genotypic predictors of coreceptor usage are likely to become a viable alternative to phenotypic assays. Indeed, recent data from the HOMER cohort and the MOTIVATE and MERIT trials show that genotype-based methods performed on populations-based samples, or “bulk” sequence data, are equivalent to the Trofile assay and that deep sequencing can actually improve the phenotypic results [65,66].

Coreceptor usage in primary HIV-1 infection
Coreceptor usage and HIV-1 transmission

Despite an extensive literature on the subject, the process of \textit{in vivo} transmission of HIV-1 remains largely unknown and most of the current models are essentially conjectural. In fact, there are virtually insurmountable difficulties in studying the earliest events of HIV-1 infection in the human species, while nonhuman primate models, albeit useful, provide only a partial and, in all likelihood, non-physiological picture. In fact, most of the observations on the acute phase of HIV-1 infection in humans are made several weeks or even months after the initial transmission event, typically in subjects who manifest clinical signs of acute retroviral syndrome. With this caveat in mind, the bulk of evidence indicates that R5 HIV-1 variants are largely prevalent during the acute phase of infection [67,68]. Even if both R5 and CXCR4-using variants are present in the donor, most often only the R5 variants are detected in the recipient [69–71]. Whether this early R5 predominance reflects a \textit{bona fide} transmission bias or a superior \textit{in vivo} fitness of R5 strains during the early phase of infection remains uncertain.

Several studies have attempted to correlate the predominance of R5 HIV-1 strains during the acute phase with a biological bottleneck inherent to the genital mucosa, variously related to trapping and inactivation of CXCR4-using virus by mucin and innate antiviral proteins, preferential transcytosis of R5 viruses in endothelial cells and/or preferential amplification of R5 viruses by resident macrophages, dendritic cells and/or Langerhans cells (reviewed in [72]. In reality, however, no conclusive evidence has been provided to indicate that CXCR4-using strains are less able or unable to sustain mucosal transmission. For example simian/human chimeric immunodeficiency viruses (SHIV) bearing an X4 HIV-1 envelope can be readily transmitted via the mucosal route in macaques, and have widely been used as a reference model [73].

Another important element that is rarely taken into consideration in the HIV-1 transmission equation is the transmitter bias, due to the fact that people with replicating CXCR4- using viruses may be in a more advanced stage of their disease and less prone to engage in risky sexual behavior [74]. If a majority of transmissions occur from asymptomatic individuals who at that time still only harbor R5 variants, then this would indeed contribute to the scarcity of transmission of CXCR4-using variants.

Post-transmission events

Another potential contributing factor in the marked R5-variant predominance during acute primary HIV-1 infection is a post-transmission amplification bias. In peripheral blood, the high proportion of CCR5·CD4+ T cells that are recruited during acute HIV-1 infection may favor R5 variants to replicate and thereby outcompete putative co-transmitted CXCR4-using variants. Moreover, the high proportion of memory/activated CCR5·CD4+ T cells present in the mucosal-associated lymphoid tissue, which is considered a major site of HIV-1 replication during primary infection [75], may provide the optimal environment for preferential R5 HIV-1 amplification. Of importance, these cells also express high levels of integrin \( \alpha 4 \beta 7 \), an important facilitator of HIV-1 infection [76].

Although primary infection with CXCR4-using HIV-1 strains is believed to be a rare event, mixed R5/X4 primary infections have been clearly documented in a few
patients studied longitudinally from an early stage post-infection [77,78]; interestingly, however, the CXCR4-using component was selectively cleared from plasma with the transition to the chronic phase in which only R5 variants could be recovered, raising the possibility that mixed R5/X4 transmission may in fact be more frequent than it appears, albeit underestimated due to late sampling, subsequent to the disappearance of the CXCR4-using component from plasma. In a recent retrospective evaluation of a large number of patients (n = 390) enrolled in the PRIMO cohort in France between 1996 and 2007, a relatively high prevalence (15.9%) of predicted CXCR4-using viruses was documented during primary infection [79]. However, subsequent phenotypic analysis of the patients in this study infected with non-subtype B variants (n=131) showed that genotypic predictions overestimated the proportion of CXCR4-using variants in non-subtype B infected patients, resulting in a much lower prevalence (0.8%) of actual CXCR4-using variants [80]. In agreement, a low prevalence of CXCR4-using viruses (4-6%) was observed in three recent cohorts of seroconverters: one from the United States (n=150) during the period 1999-2003 [81], one from France (n=133) during the period 1995-2008 [82], and one from the Netherlands (n=46) during the period 2003-2008 (ABW et al., unpublished observations). Moreover, detailed investigations of individuals experiencing primary infection and sampled prior to seroconversion (Fiebig stage I-V) using single genome amplification have revealed a consistent pattern of CCR5 dependence at this stage [67,68,83-88] indicating that any putative post-transmission amplification bias would have to occur within the first few days of exposure.

Protective effect of congenital CCR5 deficiencies

The most convincing argument in favor of the *bona fide* predominance of R5 variants in the initial transmission events is the high degree of protection from HIV-1 infection conferred by genetic deficiency of CCR5. Subjects that are homozygotes for the CCR5-Δ32 allele are highly protected from HIV-1 infection [89]. Indeed, this genotype is enriched among individuals who remain seronegative despite high-risk sexual behavior [90,91] as well among hemophiliacs who had remained HIV-negative despite exposure to batches of clotting factor that were known to be the cause of HIV infection in other hemophiliacs [92]. CCR5wt/Δ32 heterozygosity does not confer protection from HIV-1 infection, but this genotype has been associated with a significantly lower viral set point and delayed disease progression [93-96]. A second crippling polymorphism, m303, that introduces a premature stop codon in the CCR5 gene has been identified in exposed-uninfected subjects [97].

Despite the strong protective effect conferred by congenital CCR5 deficiencies, a handful of infected CCR5-Δ32 homozygotes have been reported, all invariably harboring CXCR4-dependent HIV-1 strains [98]. Interestingly, two CCR5-Δ32+/− individuals were found to harbor an inherently (not mixed) dual-tropic virus (R5X4) that remained stable over time [99], suggesting that maintenance of the CCR5-using envelope conformation might provide a selective advantage *in vivo* despite the absence of a usable receptor. Although the viral load in infected CCR5-Δ32 subjects tends to be low, a rapid depletion of circulating CD4+ T cells has been noted [98]. However, the very limited number of individuals characterized thus far makes it difficult to evaluate whether the clinical and virological course of an X4 HIV-1 infection *d’emblée* differs from that of conventional R5 HIV-1 infection in individuals with wild-type CCR5 genes. In this respect, viral variants with X4/DM phenotype have been detected in individual case reports of acute HIV-1 infections with peculiarly severe clinical manifestations [100-103], but again their number is too limited to draw any reliable conclusions and it is difficult to exclude other confounding cofactors.

Role of minor coreceptors

Usage of the so-called “minor” coreceptors during primary HIV-1 infection has only marginally been investigated. Interestingly, a high frequency of CCR3 usage during primary infection has been detected by direct cloning and expression of viral sequences, while *in vitro* culture apparently selects against CCR3 usage leading to the expansion of variants with exclusive CCR5 usage [104]. By contrast, in a few cases of primary infection with subtype-C HIV-1 studied, all of R5 phenotype, there was a surprisingly high frequency of usage of GPR15, APJ and CXCR6, but not of CCR3 [105,106]. Further studies are warranted to address the relevance of minor coreceptors in HIV-1 transmission.

Coreceptor usage in chronic HIV-1 infection

In vivo evolution of HIV-1 coreceptor usage

During the asymptomatic phase of HIV-1 infection a homogeneous R5 virus population is commonly present that generally has the ability to replicate efficiently in both T cells and monocytes/macrophages [70,71]. In many patients, a typical pattern of viral evolution has been documented during the course of the infection with the emergence, usually in concomitance with the earliest signs of disease progression, of CXCR4-using variants. However, this pattern is not consistently observed in all patients progressing to AIDS (Figure 2). For example, in patients infected with subtype-B HIV-1, variants that use CXCR4 can be isolated from approximately half of the patients who have developed AIDS [15,24,33,106-109]. Of note,
such variants may first appear during the asymptomatic phase of infection, before AIDS is diagnosed [106], albeit after an initial decline of CD4⁺ T cells [110]. Patients progressing to AIDS often harbor viral populations that can use multiple coreceptors including CCR5, CXCR4 and one or more minor coreceptors [15]. Whether a promiscuous coreceptor usage provides a selective advantage for HIV remains uncertain since most of the minor coreceptors show a low and/or tissue-specific expression pattern.

Until recently, the general consensus was that CXCR4-using variants only emerge in a certain proportion of HIV-1 infected individuals, which varies according to the viral genetic subtype. However, recent evidence has challenged this view suggesting that the prevalence of CXCR4 usage is continuously evolving over time. Data from the Amsterdam Cohort Studies on HIV infection and AIDS (ACS) show a continuously ongoing X4 conversion rate at the population level, even after AIDS diagnosis (H.S. et al., unpublished results). Thus, it seems that the emergence of CXCR4 usage is a matter of time and that some HIV-1 infected individuals die before they develop CXCR4-using variants. Molecular cloning of the viral quasispecies has documented the frequent presence of DNA sequences predictive of CXCR4 usage in blood cells even in the absence of detectable replication of such variants, as well as transient appearances of CXCR4-using strains on a background of sustained R5 persistence [50,111,112]. These observations further challenge the simplistic concept of a single and irreversible coreceptor-switching event, depicting a complex dynamic state where variant predominance is a continuously evolving process governed by multiple interactive factors. After the appearance of CXCR4-using variants, R5 variants remain present in the vast majority of patients [108,113]. Pure X4 virus populations are rather infrequently detected and often restricted to late-stage disease [114], although they have been documented earlier in rare cases of ab initio X4 transmission [70,115,116] often associated with the absence of CCR5 expression in the host [98].
Origin of CXCR4-using HIV-1 variants
Several lines of evidence suggest that CXCR4-using variants evolve in vivo from pre-existing R5 variants. Phylogenetic analysis of longitudinally obtained HIV-1 variants from individual patients has shown that although R5 and X4 variants from a single patient form separate monophyletic clusters in an unrooted tree, they do cluster together when an appropriate outgroup is used. Although this implies that R5 and CXCR4-using variants from a single individual are more related to each other than to HIV-1 variants from another person, it does not exclude that both variants may be initially transmitted together and then differentially expressed in vivo, with CXCR4-using variants maintained in a cryptic condition until immune deterioration occurs. However, the first detectable CXCR4-using variants are more closely related to the R5 variants obtained at the same time than co-existing R5 and CXCR4-using variants derived at later time points. Moreover, recently emerged CXCR4-using variants generally maintain the ability to use CCR5 and in phylogenetic trees these dual-tropic R5X4 populations cluster between pure R5 and later-stage CXCR4-using virus populations derived from the same individual. These observations are compatible with the hypothesis that the first CXCR4-using variants evolve from pre-existing R5 variants within the same individual, rather than remaining silent for many years after an initial independent transmission.

Clinical significance of CXCR4-using HIV-1 variants: cause or consequence of immune deterioration?
The emergence of CXCR4-using HIV-1 variants in a patient is almost invariably associated with a subsequent increase in the rate of decline of circulating CD4⁺ T cells, an accelerated disease progression, and a poor prognosis for survival [106] (Figure 3). Indeed, studies in the era preceding the introduction of combination antiretroviral therapy (cART) demonstrated a significant acceleration in the rate of CD4⁺ T-cell decline after the first detection of CXCR4-using variants [106,107]. However, the presence of CXCR4-using variants is not an obligatory prerequisite for disease progression and a significant proportion of individuals progress to AIDS and AIDS-related death while harboring exclusively R5 HIV-1 variants. Notably, the time from seroconversion to AIDS is not significantly different between individuals who harbor only R5 variants as compared to individuals with detectable CXCR4-using variants (Figure 4).

The accelerated CD4⁺ T-cell decline after the first appearance of CXCR4-using HIV-1 variants seems to be determined by the greater proportion of CD4⁺ T cells that express CXCR4, which provides a larger target-cell pool for the virus. Indeed, up to 90% of CD4⁺ T cells express CXCR4 whereas CCR5 expression is restricted to a smaller subset (15-35%) that express a memory/activated phenotype [117-119]. Specifically, CXCR4, but not CCR5, is expressed on naïve CD4⁺ T cells [118], a large population of non-antigen-primed T cells. Thus,
naïve CD4⁺ T cells are exclusively a target for CXCR4-using variants [120]. The pathological consequences of infection of naïve CD4⁺ T cells may be dramatic, resulting in the depletion of the largest pool of CD4⁺ T cells in the body. Considering the potential beneficial effect of an expanded target-cell population, it is puzzling that CXCR4-using variants emerge in only a proportion of infected individuals [106] even though a limited number of amino acid substitutions in V3 is sufficient to confer CXCR4-using capability to R5 variants [38,121].

It has been hypothesized that the absence of CXCR4-using variants early in HIV-1 infection may be due to their higher vulnerability to the host adaptive immune responses, in particular neutralizing antibodies. The fact that these variants appear more frequently after the initial decline of CD4⁺ T cells indeed suggests that they may represent a peculiar, congenic form of opportunistic infection. In a recent study, we found that the first appearing CXCR4-using variants are more sensitive to neutralizing antibodies directed against the CD4 binding site than their co-existing R5 variants [122]. A greater sensitivity to both monoclonal antibodies and sera from infected patients was also documented in sequential isolates derived from a cohort of perinatally-infected children (P.L. et al., unpublished data). Further evidence for a greater sensitivity of CXCR4-using variants to antibody-mediated neutralization has come from the characterization of a conserved neutralization epitope within the V3 domain of gp120: such epitope, designated D19, is invariably cryptic in R5 variants of different genetic subtypes, but it is consistently exposed in CXCR4-using variants, rendering such variants sensitive to neutralization by a specific antibody [123]. A role of cell-mediated immune responses was instead suggested by the re-emergence of CXCR4-using strains in dually-infected (R5+X4 SHIV) macaques after in vivo depletion of CD8⁺

Figure 4 Time between seroconversion (SC) and AIDS among participants in the Amsterdam Cohort Studies on HIV infection and AIDS with or without CXCR4-using variants detected prior to AIDS diagnosis. All homosexual and drug-user participants with AIDS diagnosis according to the 1993 CDC definition prior to initiation of effective antiretroviral therapy were included in the analysis. Participants were divided into 2 groups based on the presence (X4, closed circles) or absence (R5, open circles) of CXCR4-using HIV-1 variants as detected by the MT-2 assay prior to AIDS diagnosis. Time between SC and AIDS was categorized in 12-monthly intervals. The graph shows the proportion of participants per category as a percentage of the total number of participants in the group.
T cells [124]. Additional data pointing to a lower in vivo fitness of CXCR4-using variants have come from the results of clinical trials with the CCR5-antagonist maraviroc (MVC). Resistance to MVC was shown to develop by two mechanisms: a reduced drug susceptibility associated with changes in the V3 loop that allow the R5 virus to use CCR5 in its MVC-bound conformation [125] or the emergence of variants that use CXCR4 [58]. In the latter scenario, the CXCR4-using virus seems to originate from an unrecognized pretreatment reservoir, indicating that screening assay sensitivity remains to be improved. Interestingly, however, the circulating virus was shown to revert to the R5 phenotype following cessation of MVC, indicating that selective pressure acting against CXCR4 usage was preserved.

Altogether, the above observations suggest that effective host immune responses may exert a selective pressure that hinders the emergence of CXCR4-using variants. However, when the host immune competence begins to fade during the progression of HIV-1 disease, such pressure would start to wane, paving the way for the emergence of CXCR4-using variants. Although the host immune surveillance may explain, at least in part, the absence of CXCR4-using variants during the asymptomatic phase of HIV-1 infection, it cannot justify the apparent scarcity of CXCR4-using variants in the very early phase of infection when neutralizing antibodies and cytotoxic T lymphocytes are still absent. As discussed above, this may result from a lack of transmission or to the inability of recently transmitted CXCR4-using virus to compete with co-existing R5 HIV-1 during the earliest phase of infection.

R5 HIV-1 evolution in AIDS progressors without coreceptor switch

As stated above, a significant fraction of patients progresses to full-blown AIDS without experiencing an overt switch to CXCR4 usage. However, accumulating evidence indicates that in spite of their “monogamous” CCR5 use late isolates from these patients are inherently more pathogenic [126] and RANTES-resistant than early isolates [127,128]. In line with these observation is the ability of late-stage CCR5-restricted HIV-1 variants to use chimeric coreceptors in which parts of CCR5 have been replaced with segments of CXCR4 (R5 broad), whilst early CCR5-using HIV-1 variants are restricted to the use of wild-type CCR5 (R5 narrow) [127,129,130].

This in vivo evolution of CCR5-restricted HIV-1 in humans is similar to that observed in nonhuman primates infected with SIV, which never acquires CXCR4 usage even though its pathogenicity increases during the late disease stages [131]. Moreover, we have observed that the ability of R5 isolates to replicate in macrophages is progressively reduced during the course of infection, resulting in a predominantly T-cell tropic R5 HIV-1 quasispecies even before the progression to AIDS [108]. In about half of subtype-B HIV-1 infected individuals, this shift towards full T-cell tropism precedes the emergence of CXCR4 using HIV-1 variants.

R5X4 HIV-1 variants as an intermediate evolutionary stage

Evidence suggests that the evolutionary changes in the V3 loop involved in the coreceptor-usage switch are gradual and accretive, and that dual coreceptor usage (R5X4) represents an intermediate transitional phase. R5X4 viruses can be more efficient in using either CCR5 (dual-R) or CXCR4 (dual-X), or can use both coreceptors with similar efficiency [5-7]. As mentioned above, there is a continued evolution in viral coreceptor usage in vivo, resulting in a broad range of coreceptor affinities within the HIV-1 quasispecies. The limited number of amino acid substitutions required to confer CXCR4-using capability to R5 variants in vitro [38,121], combined with the high mutation rate of HIV-1 and the larger population of target cells expressing CXCR4, would predict an early and nearly universal emergence of CXCR4-using variants during chronic infection. However, the fact that CXCR4-using variants seem to develop successfully only once during HIV-1 infection [112,132], the scarcity of R5 virus variants with intermediate genotypes, and the fact that the newly emerged CXCR4-using variants differ from coexisting R5 variants by more than the minimally required number of amino acid mutations [133] altogether suggest that the virus evolves to the CXCR4-using phenotype through less-fit intermediate stages. The late emergence of CXCR4- using variants might be explained by an inability of these intermediate variants to compete with the well-established R5 virus population in spite of their broader cellular host range. Once established, however, R5X4 viruses may have developed the optimal fitness to predominate during the transition phase [134], although they may eventually be outcompeted by HIV-1 variants with a pure X4 phenotype.

Evolution of co-existing R5 and CXCR4-using HIV-1 variants

The progressive divergence between co-existing R5 and CXCR4-using clones in phylogenetic trees reflects the continuous evolution of the variable loops of gp120 following the acquisition of CXCR4 usage. This implies that the structure of gp120 continues to evolve to optimize its interaction with the coreceptors. This evolution is accompanied by improved coreceptor-binding affinity, which in turn is reflected in a decreasing sensitivity of R5 variants to inhibition by CCR5-binding chemokines and small-molecule CCR5 antagonists [127,128,135,136], as well as of CXCR4-using variants to SDF-1 and the synthetic antagonist AMD3100 [137].
Once established, CXCR4-using variants are likely to be more replication competent than R5 variants, given the broader target-cell range and the generally higher replication kinetics of CXCR4-using HIV-1 in vitro [132,138,139]. In light of these considerations, it seems paradoxical that R5 variants persist and may even expand in vivo after the emergence of CXCR4-using HIV-1 [113]. The most likely explanation for the observed coexistence of R5 and CXCR4-using variants is their distinct target cell range within an infected patient [120,140,141]. R5 variants seem to reside mainly in activated/memory CD45RO+CD4+ T cells, which express CCR5, whereas CXCR4-using variants reside in both CD45RA+ and CD45RO+CD4+ T cells [120]. Interestingly, evidence for frequent recombination events between co-existing R5 and CXCR4-using variants has been reported [142,143]. While phylogenetic trees based on envelope sequences show a clear-cut separation of coexisting R5 and CXCR4-using virus variants, this separation is not observed when the phylogenetic tree is based on gag sequences. Apparently, R5 and CXCR4-using variants can co-infect cells that express both coreceptors, thus allowing for the recombination of their genetic material.

Interestingly, the distribution of R5 and CXCR4-using variants in different blood compartments may vary. Two recent studies reported a higher prevalence of predicted CXCR4-using envelopes in PBMC than in plasma [144,145], although a third study could not confirm this discrepancy [146]. Differences in the sensitivity of the coreceptor usage predictors used may be responsible for the different study outcomes. Thus, the relevance of the choice of patient material for the determination of HIV-1 coreceptor usage remains to be established.

**Evolutionary dynamics of coreceptor usage in different HIV-1 subtype epidemics**

The different prevalence of CXCR4-using variants among different HIV-1 genetic subtypes remains puzzling. As CXCR4-using variants emerge after an accumulation of mutations, the different prevalence observed among different subtypes and CRFs may reflect the same phenomenon at the population level [147], although a direct relationship between evolutionary rate and development of CXCR4 usage has not been specifically investigated. Based on a series of recent observations, however, it is tempting to speculate that the prevalence of CXCR4-using HIV-1 is increasing with the age of the subtype epidemics (Figure 5). Indeed, phylogenetic studies have revealed that the subtype-D epidemic, which has the highest prevalence of CXCR4-using variants, is one of the oldest, while the subtype-C epidemic, which has a much lower prevalence of CXCR4-using variants, is considered one of the most recently emerged [148,149] (UNAIDS). The subtype-B HIV-1 epidemic has an intermediate pattern, both in terms of age and prevalence of CXCR4-using HIV-1 [150]. This assumption is highly speculative and not supported by all the data available at present. However, if confirmed, it would imply that all the subtype epidemics are evolving towards a higher prevalence of CXCR4-using HIV-1 variants although it is conceivable that each epidemic might reach a point of equilibrium beyond which such prevalence will not further increase.

**HIV-1 coreceptor usage and antiretroviral therapy**

Early studies of zidovudine monotherapy showed that the beneficial effect was mainly limited to persons who do not develop CXCR4-using variants [151,152]. Moreover, a trend towards increased emergence of CXCR4-using variants under zidovudine therapy was observed [151]. Further studies confirmed a differential efficacy of certain HIV-1 reverse transcriptase inhibitors against R5 and CXCR4-using viruses, with zidovudine showing a higher efficacy against R5 viruses and didanosine against CXCR4-using viruses [153,154]. This could be explained by the differential efficiency of activation of zidovudine and didanosine in CCR5-expressing activated memory T cells and CXCR4-expressing naive and resting memory T cells. Drugs that are activated equally in both types of target cells, such as lamivudine, or that did not require activation, such as the protease inhibitor (PI) ritonavir, showed equal activity against both variants [154,155].

Although several studies have reported differential responses to single-agent ART according to coreceptor usage of the HIV-1 variant present in the patient, the association between clinical efficacy of currently used cART regimens and coreceptor usage has not been rigorously evaluated. In 80-90% of asymptomatic treatment-naïve patients, only R5 virus is found [156-159], whereas recent cross-sectional studies demonstrated CXCR4-using virus in 40-55% of patients with previous antiretroviral exposure [114,159-161], probably reflecting the generally lower CD4 counts in individuals who are eligible for initiating cART [162].

Once patients are started on cART, both increased and decreased frequencies of CXCR4-using viruses have been reported [23,163-167], but neither seems to predict treatment success [168]. In patients experiencing virological failure under ART, HIV-1 tropism shifts in either direction (R5>X4 or X4>R5) have been reported in 13.2%–28.6% of subjects [162,169]. For suppressive cART, an early study reported rates of tropism shifts as high as 37.5% [167], but most recent evidence suggests that HIV-1 tropism shifts under suppressive ART are rare (3-11%) [146,170].

While initial data from the HOMER cohort showed that baseline sequences predictive of CXCR4 usage were
associated with increased risk of clinical progression during cART [171], the presence of CXCR4-using variants at baseline was not predictive of survival or treatment response after adjusting for other baseline parameters [172,173]. Instead, it was significantly associated with lower CD4 counts regardless of antiretroviral treatment exposure. Similar results were recently obtained both in a UK cohort [174] and in a Dutch cohort (ABW et al, unpublished results). It is still unclear whether the effectiveness of different regimens (e.g. PI containing or not) varies according to the coreceptor usage of the HIV-1 variants harbored by the patient at baseline.

**Conclusion**

The identification of two major HIV-1 coreceptors, CCR5 and CXCR4, the finding of their differential expression on various HIV-1 target cells, and the discovery of viral variants with differential ability to use them have significantly advanced our understanding of the clinical course of HIV-1 infection and the efficacy of antiviral therapy. The establishment of a connection between HIV-1 and the chemokine system has resulted in the development of a new drug class that directly interferes with CCR5 usage by HIV-1. These drugs not only increase the range of therapeutic options for the systemic treatment of HIV-1-infected individuals, but can also be employed as topical microbicides to prevent HIV-1 acquisition at the mucosal level. Despite these extraordinary successes, many questions regarding the clinical significance of HIV-1 coreceptor usage remain unanswered. Finding an answer to these questions may pave the way toward a deeper understanding of AIDS pathogenesis and a more effective control of the HIV-1 epidemics worldwide.

**Acknowledgements**

This work was supported in part by the Intramural Research Program of the NIAID, NIH, Bethesda, Maryland. We wish to thank all the individuals who ever worked in the Department of Clinical Viro-Immunology at the Sanquin Blood Supply Foundation and/or at the Laboratory for Viral Immune Pathogenesis at the Academic Medical Center for their helpful discussion on the topic of HIV-1 variability in AIDS pathogenesis. We thank Dr Andrew

---

**Figure 5** Hypothetical model of the evolutionary dynamics of CXCR4 usage in relation to the age of each HIV-1 subtype epidemic. Recent data suggest that the proportion of patients with detectable emergence of CXCR4-using HIV-1 variants varies in relation to the age of the different subtype epidemics, with subtype D (high CXCR4 switch rate) being the oldest and subtype C (low CXCR4 switch rate) the youngest.
Leigh-Brown for his helpful suggestion on the different ages of the HIV-1 subtype epidemics.

This article has been published as part of Journal of Translational Medicine Volume 9 Supplement 1, 2011: Differential use of CCR5 vs. CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions. The full contents of the supplement are available online at http://www.translational-medicine.com/supplements/9/S1.

Author details
1Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, and Center for Infection and Immunity Amsterdam (CINIMA) at the Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. 2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 20892, USA. *Present address: Crucell Holland BV, Leiden, The Netherlands.

Competing interests
The authors declare no competing interests.

Published: 27 January 2011

References
1. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, CCR5-alpha, and CCR5-beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
2. Deng H, Liu R, Ellmiyer W, Cheo S, Unummar D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
3. Cecilia D, KewalRamani VN, O’Malley S, Leiden, The Netherlands.
4. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Zolla-Pazner S: Different rates of disease progression of HIV type 1 infection and response to antiretroviral therapy. J Int AIDS Soc 2013, 16(4).
5. Huang W, Rziha HJ, Deeks KG, Lee HP, Petropoulos CJ, Hahn BH, Littman DR, Zolla-Pazner S: Different rates of disease progression of HIV type 1 infection and response to antiretroviral therapy. J Int AIDS Soc 2013, 16(4).
6. Abebe A, Demissie D, Goudsmit J, Bruckert E, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
7. Abebe A, Demissie D, Goudsmit J, Bruckert E, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
8. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
9. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
10. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
11. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
12. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
13. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
14. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
15. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
16. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
17. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
18. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
19. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
20. Peeters M, Vincent R, Perret JL, Lasky M, Patel D, Liegeois F, Courtaud V, Seng R, Matton T, Molinier S, Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retroviruses 1999, 20:115-121.
type I and/or uninfected wives. AIDS Res Hum Retroviruses 2002, 18:1-11.
31. Tebt DM, Ziekeng L, Kaptue L, Salmen M, Krausslich HG, Herchenröder O: Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses 2002, 18:39-48.
32. Zhong P, S Bu, Konings F, Urbanski M, Ma L, Ziekeng L, Ewane L, Aygling L, Agwara M, Saa, et al: Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses 2003, 19:167-178.
33. Esbjörnsson J, Mansson F, Martinez-Arias V, Vincic E, Biague AI, da Silva ZL, Fenyo EM, Norgren H, Medstrand P: Frequent CXCXR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease—indication of an evolving epidemic in West Africa. Retrovirology 2010, 7:23.
34. Chesebro B, Nishio J, Perryman S, Cann A, O'Brien W, Chen IS, Wehrly K: Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-lymphoma cells, and macrophages. J Virol 1991, 65:7582-7589.
35. Groenink M, Fouquier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993, 260:1513-1516.
36. O'Brien WA, Koyangi Y, Namazie A, Zhao JD, Diagne A, Idler K, Zack JA, Chen IS: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990, 348:69-73.
37. Shiota T, Levy JA, Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992, 89:9434-9438.
38. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:7677-7680.
39. Fouquier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187.
40. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA: Identification of determinants on a dualtropic human immunodeficiency virus type 1 Envelope glycoprotein that confer usage of CXCR4. J Virol 1998, 72:2509-2515.
41. Hoffman TL, Stephens EB, Narayan Q, Doms RW: HIV type 1 envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci U S A 1998, 95:11360-11365.
42. Ross TM, Cullen BR: The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in concert with a CCR-5 tropic V3 loop. Proc Natl Acad Sci U S A 1998, 95:7682-7686.
43. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
44. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA: Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000, 74:1961-1972.
45. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olton W, Kwong PD, Sattentau QJ: Selective interactions of polymers with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000, 74:1948-1960.
46. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J: A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1999, 280:1949-1953.
47. Coetzter M, Cilliers T, Ping LH, Swanstrom R, Morris L: Genetic characteristics of the V3 region associated with CXCXR4 usage in HIV-1 subtype C isolates. Virology 2006, 356:95-105.
48. Jensen MA, Coetzter M, van’t Wout AB, Morris L, Mullins JI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C and its correlation to the V3 envelope sequences. J Virol 2006, 80:4698-4704.
49. Boisvert S, Marchand M, Laviolette F, Corbel J: HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernals. Retrovirology 2008, $1:10$.
50. Jensen MA, Li FS, van’t Wout AB, Noble DC, Shiner D, He HX, McLaughlin S, Shankarappa R, Margolese R, Mullins J: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77:13376-13388.
51. Pillai S, Good B, Richman D, Corbel J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003, 19:145-149.
52. Reisch W, Hoffman N, Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002, 76:3852-3864.
53. Sing T, Low AJ, Beerewininkel N, Sander O, Cheung PK, Domingues FS, Buch J, Daumber M, Kaiser R, Lengauer T, Harrigan PR: Predicting HIV-1 coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007, 12:1097-1106.
54. Sander D, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS: Structural determinants of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 2007, 3:e58.
55. Lamers SL, Slaets M, McGrath WS, Fogel GB: Prediction of R5, X4, and R5X4 HIV-1 coreceptor usage with evolved neural networks. IEEE/ACM Trans Comput Biol Bioinform 2008, 5:291-300.
56. Westby M, Lewis M, Whitcomb J, Youle M, Poznaiak AL, James IT, Jenkins TM, Perros M, van der Ryst E: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2008, 82:5584-5593.
57. Gaschen B, Taylor J, Yuism K, Foley B, Lang D, Novitsky V, Haynes B, Bahn BH, Bhattacharya T, Kerber R: Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
58. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glasscock C, Harrigan PR: Improved Detection of CXCXR4-Using HIV by V3 Genotyping: Application of Population-Based and "Deep" Sequencing to Plasma RNA and Proviral DNA. J Acquir Immune Defic Syndr 2010.
59. Fatkenheuer G, Nelson M, Lazzarin A, Konouzina I, Hoepelman AI, Llampiris H, Hirschel B, Tepas B, Ralf F, Trotter B, et al: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.
60. Gallick GM, Laleczki, Goudesch L, Culemeks E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfelder M, et al: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
61. Su Z, Gallick GM, Krambinski A, Coalay E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, et al: Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009, 200:1724-1728.
62. McGloowen RA, Dong W, Zhong X, Mo T, Knop D, Thielen A, Chapman D, Lewis M, James IT, Heera J, et al: Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trolle assay in predicting virologic response to maraviroc of treatment-naive patients in the MERT trial. In 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA 2010.
63. Swenson LC, Dong W, Mo T, Thielen A, Jensen MA, Chapman D, James IT, Heera J, Valdez H, Harrigan PR: Large-scale application of deep sequencing using 454 technology to HIV tropism screening. In 17th...
Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2010.

67. Keefe BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557.

68. Salazar-Gonzalez JF, Baales E, Pham KT, Salazar MG, Goujard C, Martinsson T, Deveau C, Meyer L, Frange P, Chaix ML, Raymond S, Hartman S, Dekker J, van der Hoek L, Sol C, Coutinho R, Marchou B, Izopet J: High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010, 6:e1000890.

69. Long EM, Rainwater SM, Lavey ES, Mandalya K, Overbaugh J: HIV type 1 variants transmitted to women in Kenya require the CCR5 co-receptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 2002, 18:567-576.

70. van Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpier BV, Veenastra J, Boer KT, Coutinho RA, Miedema F, Schuitemaker H: Macrophe-trophic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994, 94:2060-2067.

71. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Aids 1997, 11:1170-1181.

72. Margolis L, Shattuck E: Selective transmission of CCR5-utilizing HIV-1: the ‘gateskeeper’ problem resolved? Nat Rev Microbiol 2006, 4:312-317.

73. Harouse JM, Tan RC, Gettie A, Dailey P, Marx PA, Luciw PA, Cheng-Mayer C: Characterization of human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008, 82:3952-3970.

74. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA: Identification and characterization of transmitted/founder viruses in recently infected individuals. J Virol 2009, 83:1301-1315.

75. Athreya GS, Treurnicht FK, Keele BF, Wood N, Derdeyn CA, Farmer P, Hunter E, Allen S, et al. Coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.

76. Dean M, Carrington M, Winkler C, Hutyra GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Comperts E, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Hemophlia and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophlia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.

77. Samson M, Libert F, Donnez BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cogniaux J, Forceille C, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 383:722-725.

78. Salazar-Gonzalez JF, Salazar MG, Keefe BF, Learm GH, Giorgi EE, Li H, Decker JM, Wang S, Balaiva K, Kraus MH, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289.

79. Liu R, Paxton WA, Choe S, Cerandia D, Martin SR, Horuk R, MacDonald ME, Stuhlman NJ, Koup RA: Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.

80. Sheppard HW:2305-2312.

81. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

82. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

83. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

84. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

85. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

86. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

87. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.

88. Sheppard HW: The role of viral phenotype and CCR-5 gene inherited mutations of CCR5 gene. Lancet 1997, 349:3684-3691.
immunological and virological factors to severely extreme primary HIV type 1 infection. Clin Infect Dis 2009, 48:229-238.

101. Markowitz M, Mohri M, Mehandru S, Shter A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, et al: Infection with multidrug-resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005, 363:1031-1038.

102. Mohri M, Markowitz M: In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immun Defic Syndr 2008, 48:511-521.

103. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J: Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993, 7:1035-1040.

104. Aasa-Chapman MM, Aubin K, Williams I, McKnight A: PrimaryCCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virolology 2006, 351:489-496.

105. Isaacson-Beck J, Hermann EA, Yi Y, Ractcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG: Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 2009, 83:208-8220.

106. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens FC, Termontte M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.

107. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.

108. Schuitemaker H, Koot M, Kootstra NA, Derksens MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenger JK, Miedema F, Termontte M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocyteotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360.

109. Koot M, Vos AH, Keet IP, de Goede RE, Derksens MW, Terpstra FG, Coutinho RA, Miedema F, Termontte M: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49-54.

110. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Leifrink Schattenger JK, Reiss P, Termontte M, Lange JM, Schuitemaker H: Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999, 179:254-258.

111. Iida S, Gatanaga H, Shioda T, Nagai Y, Kobayashi N, Shimada K, Kimura S, Iwamoto O, Oka S: HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses 1997, 13:1597-1609.

112. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Uphuch D, Farzadegan H, Gupta P, Rinaldo CR, Lear M, He X, et al: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10469-10502.

113. Koot M, van de Wouw AB, Kootstra NA, de Goede RE, Termontte M, Schuitemaker H: Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Clin Microbiol 1996, 173:349-354.

114. Melbye T, Desponte D, Demasi R, Helvik-Snager G, Greenberg ML, Graham N: HIV-1 coreceptor use in triple-class-treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194:238-246.

115. Huang W, Esfiehan SH, Toma J, Staviski E, Whitcomb JM, Jackson JB, Guay L, Musoke P, Parkin N, Petropoulos CJ: Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-child pairs. AIDS 2009, 23:1903-1908.

116. Weiss SH, Goodert JJ, Gartner S, Popovic M, Waters D, Markham P, di Marco Veronese F, Gail MH, Barley KE, Gibbons J, et al: Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science 1998, 239:68-71.

117. Berkowitz RO, Beckerman KP, Schall TJ, McCune JM: CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol 1998, 161:3702-3710.

118. Beut CC, Wu L, Horxie JA, Springer TA, Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997, 94:1925-1930.

119. de Roda Husman AM, Bliek H, Brouwer M, Schuitemaker H: CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Infect Dis 1999, 163:4597-4603.

120. Blaak H, van 't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H: In vivo HIV-1 infection of CD45RA+ (CD4+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline. Proc Natl Acad Sci USA 2000, 97:1269-1274.

121. Pastore C, Nederlic R, Rama A, Pantow S, Ratiner L, Mosier DE: Human immunodeficiency virus type 1 coreceptor switching: VI/VI gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80:750-758.

122. Bunnik EM, Quakkelkier ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H: Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 2007, 81:525-531.

123. Lusso P, Earl PL, Sironi F, Santoro F, Rapamonti C, Scarletti G, Longhi R, Berger EA, Burastero SE: Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 2005, 79:6957-6968.

124. Harouse JM, Buckner C, Giette A, Fuller R, Bohm R, Blanchard J, Cheng-Mayer C: CD8+ T cell-mediated CXC chemokine receptor 4-simian-human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A 2003, 100:10977-10982.

125. Westby M, Smith-Burchell C, Mari L, Lewis M, Mosley M, Stockdale MA, Dor P, Caramella G, Pennos M: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81:2359-2371.

126. Scoggin RM, Taylor JR Jr, Patre J, van't Wout AB, Schuitemaker H, Camerini D: Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol 2000, 74:3205-3216.

127. Karlson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, Olde B, Ovman C, Jansson M, Fenyo EM: Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004, 78:11807-11815.

128. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiejstra H, Schuitemaker H: Decreasing sensitivity to RANTES (regulated on activation, normally T cell expressed and secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003, 188:864-872.

129. Cavourri D, Karlson I, Zanchetta M, Antonsson L, Pilebiani A, Gaqunto C, Fenyo EM, De Rossi A, Scarletti G: HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS One 2008, 3:e3292.

130. Karlson I, Antonsson L, Shi Y, Karlsson A, Albert J, Olde B, Ovman C, Fenyo EM: HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003, 17:2561-2569.

131. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J: HIV-1 biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003, 17:2561-2569.
HIV in patients with ongoing treatment failure on HAART. *J Clin Virol* 2006, 37:300-304.

170. Soulie C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duivier C, Costagliola D, Katlama C, Calvez V: HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. *Aids* 2007, 21:2243-2245.

171. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman KG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JS, Harrigan PR: Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. *Aids* 2004, 18:F1-9.

172. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. *Aids* 2007, 21:F17-24.

173. Low AJ, Marchant D, Brumme CJ, Brumme ZL, Dong W, Sing T, Hogg RS, Montaner JS, Gill V, Cheung PK, Harrigan PR. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. *AIDS Res Hum Retroviruses* 2008, 24:219-228.

174. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G: The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. *Clin Infect Dis* 2008, 46:1617-1623.

Cite this article as: Schuitemaker et al. Clinical significance of HIV-1 coreceptor usage. *Journal of Translational Medicine* 2010 9(Suppl 1):S5.